Recent Runs

60 stored validator runs for this network. Search or pick one to inspect below.

Select Run

Consensus Run

mcr_f59f8dd8bd102a06665a36ef

Source run_20260831_211555_dbe224 · started Oct 13, 11:26 UTC

Mainnet Testnet

StatusHealthy

Completed

Run Time

36m 15s

Cases

200

Reviewers

Responses

Qualified

Mean Score

0.741

Source Batch

batch_20260831_660a19ea391f

Reviewer Results

Consensus scores and qualification results for miners who received this round.

UID	Hotkey	Status	Score	Qualified
UID 251	5HDsDwo...NZSB4	responded	1.000	Yes
UID 122	5EnpfGZ...FENnB	non_response	0.000	No
UID 164	5CoLWok...dR8wp	responded	1.000	Yes
UID 73	5HDmNaB...xCsrq	responded	0.990	Yes
UID 187	5FFG8zd...py6Gd	responded	0.980	Yes
UID 144	5CJFg65...QFYUV	responded	1.000	Yes
UID 149	5CPkdLy...TFhGQ	responded	1.000	Yes
UID 156	5ChwW15...fQVyW	non_response	0.000	No
UID 190	5DcTqTH...KnJV7	non_response	0.000	No
UID 207	5H4GiuY...cr5BU	responded	0.960	Yes
UID 119	5E9SmUN...jSoiV	responded	0.970	Yes
UID 160	5FTVoVJ...5APoK	responded	0.960	Yes
UID 184	5Hh3Wh2...jVwWe	responded	1.000	Yes
UID 221	5FsjxHC...ANZD6	responded	0.980	Yes
UID 222	5GLQFJC...9jSii	responded	1.000	Yes
UID 250	5DMKPFd...j3acZ	non_response	0.000	No
UID 48	5Cf1sea...x44cj	responded	0.970	Yes
UID 54	5HBXE8Z...vjmAU	responded	1.000	Yes
UID 137	5Ec8whh...WQEvm	non_response	0.000	No
UID 165	5GP12H7...64NaS	responded	1.000	Yes

Case Votes

Open a case to compare its candidates and see how every reviewer voted.

Case 1openalex_w4200355303Both valid · 14 votes · 0.714 agreement · 1 failed review

Candidate A

The therapeutic effect of local arginine bacteria plus checkpoint blockade is context-dependent: tumor control and immune memory observed in one mouse tumor setting do not automatically transfer to another tumor rechallenge setting.

Candidate B

Tumor rechallenge 90 days after complete tumor remission also confirmed the anti-tumor memory of T cells against MC38 cells in mice, which was, however, not applicable in the context of melanoma B16 cells rechallenge.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.720	Candidate B quotes the source directly (MC38 memory confirmed at 90 days, not applicable to B16), and candidate A is a faithful, appropriately hedged generalization of that contrast.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source text stating that tumor rechallenge confirmed memory against MC38 but not applicable to B16, indicating context-dependence.
UID 735HDmNaB...xCsrq	Both valid	0.950	Both candidate statements are directly supported by the source's report of MC38 rechallenge memory versus B16 rechallenge non-applicability and the noted difference in effective anti-tumor T-cell response.
UID 1875FFG8zd...py6Gd	Candidate B	0.980	Candidate B is directly and specifically stated in the source. Candidate A is a broader interpretation that is only partially supported because it generalizes the observation to therapeutic effect and context dependence.
UID 1445CJFg65...QFYUV	Both valid	0.800	Both reflect the MC38 versus B16 rechallenge contrast.
UID 1495CPkdLy...TFhGQ	Both valid	0.750	B is a verbatim quote; A is a faithful paraphrase of the contrast.
UID 2075H4GiuY...cr5BU	Candidate B	0.950	Candidate B is a direct paraphrase of the source text stating that rechallenge confirmed memory in MC38 but not in B16 contexts.
UID 1195E9SmUN...jSoiV	Candidate B	0.950	The source text explicitly states that tumor rechallenge confirmed anti-tumor memory for MC38 cells but was 'not applicable' for melanoma B16 cells rechallenge.
UID 1605FTVoVJ...5APoK	Review failed	-	Review failed after retries: Expecting ',' delimiter: line 1 column 351 (char 350)
UID 1845Hh3Wh2...jVwWe	Both valid	0.700	Both reflect the MC38 memory vs B16 non-applicability contrast; A is a faithful paraphrase, B is a verbatim quote.
UID 2215FsjxHC...ANZD6	Both valid	0.900	Candidate A correctly identifies the context-dependent efficacy and Candidate B accurately reports the specific rechallenge outcomes for MC38 and B16 models as stated in the source.
UID 2225GLQFJC...9jSii	Both valid	0.700	Both reflect the MC38 memory vs B16 non-applicability contrast.
UID 485Cf1sea...x44cj	Both valid	0.950	Both candidates are faithful to the reported MC38 memory finding and the explicitly stated non-applicability in the B16 rechallenge context, supporting the context-dependent interpretation.
UID 545HBXE8Z...vjmAU	Candidate B	0.780	Candidate B restates the source sentence exactly: memory against MC38 confirmed on rechallenge 90 days after complete remission, explicitly not applicable to B16 rechallenge. Candidate A is a broader inference about context-dependence that the passage only implies, so B is more directly supported and more faithful in scope.
UID 1655GP12H7...64NaS	Both valid	0.800	Both match the MC38 versus B16 rechallenge contrast.

Case 2openalex_w4200355303Both valid · 15 votes · 0.667 agreement

Candidate A

Candidate B

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.700	Both reflect the MC38 memory versus B16 no-memory contrast.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source text describing context-dependent immune memory in MC38 vs B16 rechallenge.
UID 735HDmNaB...xCsrq	Both valid	0.900	Both claims are directly supported by the source statement that tumor rechallenge confirmed memory against MC38 but not B16.
UID 1875FFG8zd...py6Gd	Both valid	0.960	The broader context-dependence claim and the narrower observation are both supported. The source reports durable anti-tumor memory after MC38 rechallenge but explicitly says this was not applicable to B16 rechallenge.
UID 1445CJFg65...QFYUV	Both valid	0.800	Both reflect the MC38 memory versus B16 rechallenge contrast.
UID 1495CPkdLy...TFhGQ	Both valid	0.750	B is verbatim; A paraphrases the MC38 vs B16 contrast.
UID 2075H4GiuY...cr5BU	Candidate B	0.950	Candidate B accurately quotes the source text regarding the confirmed anti-tumor memory in MC38 rechallenge and its lack of applicability to B16 rechallenge.
UID 1195E9SmUN...jSoiV	Candidate B	0.950	Candidate B is a direct paraphrase of the source text which explicitly states that anti-tumor memory was confirmed for MC38 rechallenge but not applicable for B16 rechallenge.
UID 1605FTVoVJ...5APoK	Candidate B	0.950	Candidate B accurately reflects the source text stating that anti-tumor memory was confirmed for MC38 rechallenge but not applicable for B16 rechallenge.
UID 1845Hh3Wh2...jVwWe	Both valid	0.700	A paraphrases the MC38 vs B16 contrast and B quotes it.
UID 2215FsjxHC...ANZD6	Candidate B	0.900	Candidate B directly quotes the source text regarding the specific rechallenge outcomes for MC38 and B16 models.
UID 2225GLQFJC...9jSii	Both valid	0.700	B is a verbatim quote; A paraphrases the same contrast.
UID 485Cf1sea...x44cj	Both valid	0.900	Both claims are directly supported by the source text describing context-dependent immune memory in MC38 vs B16 rechallenge.
UID 545HBXE8Z...vjmAU	Candidate B	0.780	Candidate B reproduces the source's own sentence atom for atom (90-day rechallenge, confirmed T-cell memory against MC38, not applicable for B16 rechallenge), so every number, population and direction is directly established. Candidate A is a looser interpretive generalization ('context-dependent', 'do not automatically transfer') whose scope is vaguer and which is only implied by the same passage, so B is the more directly supported and more faithful statement.
UID 1655GP12H7...64NaS	Both valid	0.800	Both reflect MC38 memory versus no memory in B16 rechallenge.

Case 3openalex_w4200355303Both valid · 15 votes · 0.533 agreement

Candidate A

Increasing local arginine availability can restore or support T-cell activity and thereby create a complementary mechanism for anti-PD-L1 immunotherapy.

Candidate B

Local metabolic support of T cells and checkpoint blockade act synergistically rather than additively: combining arginine-producing bacteria with PD-L1 blockade converts partial tumor control into complete tumor eradication in most treated hosts.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate B	0.500	B is grounded in the 74% eradication and synergy; A is vaguer, though both are broadly consistent.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source: candidate_a by the description of arginine restoring T-cell activity and complementing anti-PD-L1, candidate_b by the explicit statement of synergistic effect and complete eradication in 74% of mice.
UID 735HDmNaB...xCsrq	Both valid	0.900	Both claims are directly supported by the source: L-Arg bacteria reactivate T cells and synergistically enhance anti-PD-L1 therapy, yielding complete eradication in 74% of MC38-bearing mice.
UID 1875FFG8zd...py6Gd	Both valid	0.900	Both candidates are supported by the source. Candidate A states the mechanistic relationship between local arginine support, T-cell activity, and anti-PD-L1 therapy; Candidate B is a more specific refinement describing synergistic treatment and the reported complete eradication rate in MC38-bearing mice.
UID 1445CJFg65...QFYUV	Candidate B	0.550	The 74% eradication and synergy are reported, but A is a looser generalization.
UID 1495CPkdLy...TFhGQ	Candidate B	0.550	74% complete eradication with synergy is reported; B matches closely.
UID 2075H4GiuY...cr5BU	Both valid	0.900	The source text explicitly states that L-Arg bacteria reactivate T cells (supporting candidate_a) and synergistically enhance anti-PD-L1 therapy to achieve complete tumor eradication in 74% of mice (supporting candidate_b).
UID 1195E9SmUN...jSoiV	Both valid	0.900	The source explicitly states that L-Arg bacteria reactivate T cells (supporting candidate_a) and synergize with anti-PD-L1 to achieve complete eradication in 74% of mice (supporting candidate_b).
UID 1605FTVoVJ...5APoK	Both valid	0.900	The source explicitly states that L-Arg bacteria reactivate T cells (supporting candidate_a) and synergize with anti-PD-L1 to achieve complete eradication in 74% of mice (supporting candidate_b).
UID 1845Hh3Wh2...jVwWe	Both valid	0.600	74% eradication with synergy reported; B's 'most hosts' is consistent.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source text explicitly supports both the mechanistic role of arginine in T-cell activity and the specific synergistic outcome of complete eradication in 74% of MC38 mice when combining L-Arg bacteria with anti-PD-L1.
UID 2225GLQFJC...9jSii	Candidate B	0.500	B is supported by synergy and 74% eradication; it states 'rather than additively' and 'partial control' beyond the text, but is closer to the reported result.
UID 485Cf1sea...x44cj	Candidate A	0.900	Source states L-Arg bacteria reactivate T cells and synergistically enhance anti-PD-L1 therapy, supporting local arginine as a complementary mechanism.
UID 545HBXE8Z...vjmAU	Candidate A	0.800	Candidate B adds two unsupported atoms: the source reports a 'synergistic' effect but never contrasts synergy with additivity (no additivity analysis is reported), and it never characterizes the model as an 'immunogenic murine colon carcinoma' — that identification comes from outside knowledge. Candidate A's atoms (raising local Arg, reactivating T cells, complementing anti-PD-L1 in mouse MC38 tumors) are all stated in the source.
UID 1655GP12H7...64NaS	Candidate A	0.550	B asserts synergy versus additivity and conversion of partial control, beyond the text; A is supported.

Case 4openalex_w4200355303Both valid · 14 votes · 0.571 agreement · 1 failed review

Candidate A

Increasing local arginine availability can restore or support T-cell activity and thereby create a complementary mechanism for anti-PD-L1 immunotherapy.

Candidate B

The combined treatment of L-arginine bacteria and anti-PD-L1 leads to complete tumor eradication in a subset of tumor models.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate A	0.500	B says a subset of tumor models, while the 74% eradication is reported only for MC38; A is more faithful.
UID 1645CoLWok...dR8wp	Both valid	0.900	The source states that L-Arg bacteria reactivate T cells and synergize with anti-PD-L1, leading to complete tumor eradication in 74% of MC38-bearing mice, supporting both claims.
UID 735HDmNaB...xCsrq	Both valid	0.920	The source supports that local arginine modulation reactivates T cells and adds to anti-PD-L1 efficacy, and it also reports complete tumor eradication in MC38-bearing mice, so both candidate claims are directly supported.
UID 1875FFG8zd...py6Gd	Both valid	0.980	Both claims are supported and are compatible: the source describes T-cell-dependent synergistic anti-PD-L1 activity from intratumoral L-Arg bacteria and reports complete tumor eradication in 74% of MC38-bearing mice, which is a subset outcome.
UID 1445CJFg65...QFYUV	Candidate B	0.700	The text reports complete eradication in 74% of MC38 mice.
UID 1495CPkdLy...TFhGQ	Candidate B	0.600	B is directly supported (complete eradication in 74% of MC38 mice); A is inference.
UID 2075H4GiuY...cr5BU	Review failed	-	Review failed after retries: Extra data: line 1 column 435 (char 434)
UID 1195E9SmUN...jSoiV	Both valid	0.900	Candidate A is supported by the text describing Arg recycling to reactivate T cells and synergize with anti-PD-L1, while Candidate B is directly supported by the statement that the combination resulted in complete tumor eradication in 74% of MC38-bearing mice.
UID 1605FTVoVJ...5APoK	Candidate A	0.950	The source explicitly states that L-Arg bacteria reactivate T cells and synergize with anti-PD-L1, supporting the claim about restoring T-cell activity.
UID 1845Hh3Wh2...jVwWe	Both valid	0.700	Arg supports T cells and synergy with anti-PD-L1 is reported; complete eradication in 74% of MC38 mice supports B.
UID 2215FsjxHC...ANZD6	Both valid	0.900	Candidate A is supported by the text's description of Arg recycling to reactivate T cells and synergize with anti-PD-L1, while Candidate B is directly supported by the statement that complete tumor eradication occurred in 74% of MC38-bearing mice.
UID 2225GLQFJC...9jSii	Candidate B	0.600	74% complete eradication in MC38 supports B; A's restoring T-cell activity is more interpretive but plausible; B is more direct.
UID 485Cf1sea...x44cj	Both valid	0.900	The source supports candidate_a's claim that arginine availability supports T-cell activity and complements anti-PD-L1 therapy, and also supports candidate_b's claim of complete tumor eradication in 74% of MC38 mice with combined treatment.
UID 545HBXE8Z...vjmAU	Candidate A	0.620	Candidate B shifts the population atom: the source reports complete eradication in 74% of MC38-bearing mice — a subset of mice in a single model — not in 'a subset of tumor models'; in the B16 setting the combination only inhibited tumor growth, and only with OT-I T-cell transfer. Candidate A's atoms (local Arg supporting T-cell activity as a complementary mechanism for anti-PD-L1 in mouse MC38) are all stated.
UID 1655GP12H7...64NaS	Both valid	0.700	Complete eradication in 74% of MC38 mice supports B; A is supported.

Case 5openalex_w4200355303Both valid · 14 votes · 0.857 agreement · 1 failed review

Candidate A

Candidate B

Arginine-based metabolic modulation combined with checkpoint blockade can establish durable anti-tumor immunological memory, not merely transient tumor control.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate B	0.550	B matches the MC38 memory finding; A's claim is a general context-dependence inference.
UID 1645CoLWok...dR8wp	Both valid	0.900	The source confirms durable memory for MC38 but not for B16, supporting both context-dependence and memory establishment.
UID 735HDmNaB...xCsrq	Both valid	0.900	The source reports 90-day rechallenge memory against MC38 but states this memory was not applicable to B16 rechallenge, supporting both the durable-memory and context-dependence claims.
UID 1875FFG8zd...py6Gd	Both valid	0.960	Both claims are directly supported. The source reports durable anti-tumor memory after MC38 rechallenge, while also explicitly noting that this result did not apply to the B16 rechallenge context, supporting both durable memory in the stated setting and context dependence.
UID 1445CJFg65...QFYUV	Both valid	0.700	MC38 memory 90 days after remission is reported, and the B16 difference is also reported.
UID 1495CPkdLy...TFhGQ	Both valid	0.700	MC38 memory confirmed at 90 days while B16 not; both consistent.
UID 2075H4GiuY...cr5BU	Review failed	-	Review failed after retries: Extra data: line 1 column 347 (char 346)
UID 1195E9SmUN...jSoiV	Both valid	0.900	The source text explicitly confirms that L-Arg bacteria plus anti-PD-L1 induced durable memory in MC38 models but failed to do so in B16 melanoma models without T-cell transfer, supporting both the context-dependency and the establishment of memory claims.
UID 1605FTVoVJ...5APoK	Both valid	0.900	The source explicitly confirms durable memory in MC38 rechallenge and context-dependent efficacy where B16 required T-cell transfer, supporting both candidates.
UID 1845Hh3Wh2...jVwWe	Both valid	0.700	MC38 rechallenge at 90 days confirmed memory but not in B16, supporting both.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source explicitly confirms durable memory in MC38 rechallenge and context-dependent efficacy where B16 rechallenge failed without specific T-cell transfer.
UID 2225GLQFJC...9jSii	Both valid	0.650	A matches MC38/B16 contrast; B matches MC38 memory 90 days after remission.
UID 485Cf1sea...x44cj	Both valid	0.900	The source confirms anti-tumor memory for MC38 but not for B16, supporting both context-dependence and the existence of durable memory in the MC38 setting.
UID 545HBXE8Z...vjmAU	Candidate B	0.700	Candidate B's atoms all hold: rechallenge of completely remitted mice 90 days later confirmed anti-tumor T-cell memory against MC38, and its qualifier correctly limits memory to the original tumor type because the source says this was not applicable for B16 rechallenge. Candidate A states the same passage only as a vaguer non-transfer generalization, so B is the more complete and more directly supported reading.
UID 1655GP12H7...64NaS	Both valid	0.700	MC38 memory 90 days after remission is reported; B limits to MC38, and A's context-dependence is supported.

Case 6openalex_w4200355303Candidate B · 15 votes · 0.600 agreement

Candidate A

Increasing local arginine availability can restore or support T-cell activity and thereby create a complementary mechanism for anti-PD-L1 immunotherapy.

Candidate B

Intratumoral injection of L-Arg bacteria shows synergistic anti-tumor effect with anti-PD-L1 antibodies, depends on T cell activation, and causes significant tumor eradication and prolonged survival of tumor-bearing mice.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate B	0.600	B restates Fig. 1 caption nearly verbatim; A is a general inference, less directly stated, and B is directly supported.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source: candidate_a is supported by the general mechanism described, and candidate_b is explicitly stated in the figure caption and text.
UID 735HDmNaB...xCsrq	Both valid	0.900	Both claims are directly supported by the source: candidate_a is a general statement about arginine availability supporting T-cell activity and complementing anti-PD-L1, and candidate_b is a specific description of the intratumoral L-Arg bacteria study showing synergy, T cell dependence, and tumor eradication.
UID 1875FFG8zd...py6Gd	Both valid	0.970	Candidate A provides the mechanistic interpretation that local arginine availability supports T-cell activity and complements anti-PD-L1 therapy. Candidate B states the same finding in the specific intratumoral mouse experiment, including T-cell dependence, tumor eradication, and prolonged survival. The claims are compatible, with Candidate B being more specific.
UID 1445CJFg65...QFYUV	Candidate B	0.700	B restates Fig. 1 legend and text directly; A is a generalization, though plausible.
UID 1495CPkdLy...TFhGQ	Candidate B	0.800	B restates Fig. 1 caption; A is a general inference, though plausible, B is directly stated.
UID 2075H4GiuY...cr5BU	Candidate B	0.900	The source explicitly states that intratumoral L-Arg bacteria synergize with anti-PD-L1, depend on T cell activation, and cause significant tumor eradication and prolonged survival in MC38 models.
UID 1195E9SmUN...jSoiV	Candidate B	0.950	Candidate B accurately reflects the specific findings in MC38 mice regarding synergy, T-cell dependence, and survival outcomes described in the source text and figure caption.
UID 1605FTVoVJ...5APoK	Candidate B	0.950	The source explicitly states that intratumoral injection of L-Arg bacteria synergizes with anti-PD-L1, depends on T cell activation, and causes significant tumor eradication and prolonged survival in MC38 models.
UID 1845Hh3Wh2...jVwWe	Both valid	0.800	Figure legend matches B exactly; A is consistent.
UID 2215FsjxHC...ANZD6	Candidate B	0.950	Candidate B is directly supported by the source text and figure caption which explicitly state that intratumoral L-Arg bacteria synergize with anti-PD-L1, depend on T cell activation, and cause significant tumor eradication and prolonged survival in MC38 mice.
UID 2225GLQFJC...9jSii	Candidate B	0.600	B restates the Fig. 1 legend directly.
UID 485Cf1sea...x44cj	Both valid	0.900	Both claims are directly supported by the source: candidate_a's general mechanism is described, and candidate_b's specific findings are explicitly stated in the text and figure caption.
UID 545HBXE8Z...vjmAU	Candidate B	0.850	Every atom of candidate B appears in the source's figure statement: intratumoral L-Arg bacteria synergize with anti-PD-L1 antibodies, the effect depends on T cell activation, and it causes significant tumor eradication and prolonged survival of tumor-bearing mice. Candidate A is supported but drops the T-cell dependence and survival atoms, so the fully supported, more specific candidate is stronger.
UID 1655GP12H7...64NaS	Both valid	0.750	B restates the Fig. 1 legend; A is consistent.

Case 7openalex_w4200355303Both valid · 15 votes · 0.600 agreement

Candidate A

Increasing local arginine availability can restore or support T-cell activity and thereby create a complementary mechanism for anti-PD-L1 immunotherapy.

Candidate B

Metabolic support from arginine-producing bacteria can sensitize tumors to checkpoint blockade, converting partial anti-tumor responses into durable complete eradication.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate A	0.500	B claims conversion of partial responses to complete eradication, which is not reported; A is a looser but consistent framing.
UID 1645CoLWok...dR8wp	Candidate A	0.850	The source supports that increasing local arginine via L-Arg bacteria reactivates T cells and synergizes with anti-PD-L1, while candidate_b's 'partial anti-tumor responses' baseline is not explicitly stated.
UID 735HDmNaB...xCsrq	Both valid	0.900	Both claims are directly supported by the source's description of L-Arg bacteria enhancing anti-PD-L1 therapy and T-cell activity, leading to complete tumor eradication.
UID 1875FFG8zd...py6Gd	Both valid	0.960	Both claims are supported by the source. The article reports synergistic anti-PD-L1 activity in mouse MC38 tumors and states that the combination produced complete tumor eradication in 74% of mice. The second claim is a compatible refinement of the first under the stated MC38 experimental conditions.
UID 1445CJFg65...QFYUV	Candidate A	0.550	B claims conversion of partial responses into durable eradication, which compares to monotherapy and is not stated, while A is a supported mechanistic framing.
UID 1495CPkdLy...TFhGQ	Candidate A	0.550	B claims conversion of partial responses, not explicitly shown; A is generally supported.
UID 2075H4GiuY...cr5BU	Both valid	0.900	The source explicitly states that L-Arg bacteria restore T-cell activity (supporting candidate_a) and synergize with anti-PD-L1 to achieve complete tumor eradication in 74% of mice (supporting candidate_b).
UID 1195E9SmUN...jSoiV	Both valid	0.900	The source text explicitly states that L-Arg bacteria reactivate T cells (supporting candidate_a) and result in complete tumor eradication in 74% of mice when combined with anti-PD-L1 (supporting candidate_b).
UID 1605FTVoVJ...5APoK	Both valid	0.900	The source explicitly states that L-Arg bacteria restore T-cell activity and synergize with anti-PD-L1 to achieve complete tumor eradication in MC38 models.
UID 1845Hh3Wh2...jVwWe	Both valid	0.650	Combination yielded complete eradication in 74% of MC38 mice, consistent with B; A is supported.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source text explicitly supports both the mechanism of arginine restoring T-cell activity (candidate_a) and the outcome of complete tumor eradication via combination therapy (candidate_b).
UID 2225GLQFJC...9jSii	Both valid	0.550	Both consistent with synergy, T-cell dependence and complete eradication in MC38.
UID 485Cf1sea...x44cj	Both valid	0.950	Both claims are directly supported by the source: local arginine availability restores T-cell activity and synergizes with anti-PD-L1, leading to durable complete eradication in the MC38 model.
UID 545HBXE8Z...vjmAU	Candidate B	0.620	Candidate B's atoms are each present: L-Arg bacteria alone inhibited tumor growth (partial control), the combination with anti-PD-L1 was synergistic and gave complete eradication in 74% of MC38-bearing mice, and the 90-day rechallenge memory supports 'durable'. Candidate A is supported but less specific, and B's added details (MC38 model, intratumoral route, combination with anti-PD-L1) are all in the source.
UID 1655GP12H7...64NaS	Candidate A	0.600	B claims converting partial responses to eradication, not directly reported (no monotherapy comparison of eradication); A is supported.

Case 8openalex_w4200355303Both valid · 15 votes · 0.667 agreement

Candidate A

Increasing local arginine availability can restore or support T-cell activity and thereby create a complementary mechanism for anti-PD-L1 immunotherapy.

Candidate B

Intratumoral injection of L-Arg bacteria shows a synergistic anti-tumor effect with anti-PD-L1 antibodies, and this effect is dependent on T cell activation.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate B	0.650	B matches the Fig. 1 caption statement directly.
UID 1645CoLWok...dR8wp	Both valid	0.950	The source directly reports T-cell-dependent synergy between intratumoral L-Arg bacteria and anti-PD-L1, and frames local arginine elevation as a metabolic strategy that supports T-cell activity and improves immunotherapy.
UID 735HDmNaB...xCsrq	Both valid	0.900	Both claims are directly supported by the source: candidate_a is supported by the general mechanism and synergy described, and candidate_b is explicitly stated in the figure caption and text.
UID 1875FFG8zd...py6Gd	Both valid	0.980	Both claims are supported and compatible. The broader claim describes arginine-mediated T-cell support and complementary anti-PD-L1 activity, while the narrower claim specifies the reported intratumoral mouse finding that the combination effect depends on T-cell activation.
UID 1445CJFg65...QFYUV	Candidate B	0.700	B matches the Fig. 1 legend directly.
UID 1495CPkdLy...TFhGQ	Candidate B	0.700	B matches the figure caption directly.
UID 2075H4GiuY...cr5BU	Both valid	0.900	The source explicitly states that L-Arg bacteria synergize with anti-PD-L1 and this effect is dependent on T cell activation, supporting both candidates.
UID 1195E9SmUN...jSoiV	Both valid	0.900	The source explicitly states that L-Arg bacteria synergize with anti-PD-L1 and reactivate T cells, while also noting that Arg is essential for T cell responsiveness, supporting both claims.
UID 1605FTVoVJ...5APoK	Both valid	0.900	The source explicitly states that L-Arg bacteria synergize with anti-PD-L1 and this effect is dependent on T cell activation, supporting both candidates.
UID 1845Hh3Wh2...jVwWe	Both valid	0.750	Figure legend states synergy dependent on T cell activation; A is consistent.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source explicitly states that L-Arg bacteria synergize with anti-PD-L1 in MC38 models and that this effect is dependent on T cell activation, supporting both candidates.
UID 2225GLQFJC...9jSii	Candidate B	0.600	B restates the figure legend directly.
UID 485Cf1sea...x44cj	Both valid	0.900	The source supports both claims: it describes that increasing local arginine restores T-cell activity and synergizes with anti-PD-L1, and explicitly states that intratumoral L-Arg bacteria show synergistic anti-tumor effect with anti-PD-L1 dependent on T cell activation.
UID 545HBXE8Z...vjmAU	Candidate B	0.850	Candidate B matches the source's own figure statement atom for atom: intratumoral injection of L-Arg bacteria shows a synergistic anti-tumor effect with anti-PD-L1 antibodies that is dependent on T cell activation. Candidate A is supported but less specific and omits the T-cell-dependence atom, so the fully supported, more specific candidate is stronger.
UID 1655GP12H7...64NaS	Both valid	0.750	Synergy and T-cell dependence stated in the Fig. 1 legend.

Case 9openalex_w4200355303Both valid · 15 votes · 0.667 agreement

Candidate A

Increasing local arginine availability can restore or support T-cell activity and thereby create a complementary mechanism for anti-PD-L1 immunotherapy.

Candidate B

Combined treatment of L-Arg bacteria and anti-PD-L1 therapy resulted in complete tumor eradication in 74% of MC38-bearing mice.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate B	0.800	74% complete eradication in MC38 mice is stated explicitly.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source: candidate_a's mechanistic role of arginine in T-cell activity and combination therapy is described, and candidate_b's specific 74% eradication rate is explicitly reported.
UID 735HDmNaB...xCsrq	Both valid	0.950	Both claims are directly supported: the source reports L-Arg bacteria reactivating T cells and synergizing with anti-PD-L1, and states complete tumor eradication in 74% of MC38-bearing mice.
UID 1875FFG8zd...py6Gd	Both valid	0.990	Both claims are directly supported and are compatible refinements. The source describes synergistic anti-PD-L1 effects of L-Arg bacteria and explicitly reports complete tumor eradication in 74% of MC38-bearing mice under the combined treatment.
UID 1445CJFg65...QFYUV	Candidate B	0.800	The 74% eradication in MC38-bearing mice is stated explicitly.
UID 1495CPkdLy...TFhGQ	Candidate B	0.800	74% complete eradication in MC38 mice is stated explicitly.
UID 2075H4GiuY...cr5BU	Both valid	0.900	The source text explicitly states that L-Arg bacteria synergistically enhanced anti-PD-L1 therapy resulting in complete tumor eradication in 74% of MC38-bearing mice and explains this mechanism by reactivating T cells through local arginine availability.
UID 1195E9SmUN...jSoiV	Both valid	0.950	The source explicitly states that L-Arg bacteria synergize with anti-PD-L1 to reactivate T cells and result in complete tumor eradication in 74% of MC38-bearing mice.
UID 1605FTVoVJ...5APoK	Both valid	0.950	The source text explicitly states that L-Arg bacteria reactivate T cells to support anti-PD-L1 therapy and reports complete tumor eradication in 74% of MC38-bearing mice under combined treatment.
UID 1845Hh3Wh2...jVwWe	Both valid	0.800	74% complete eradication in MC38 is stated; A is supported.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source explicitly states that L-Arg bacteria restore T-cell activity to synergize with anti-PD-L1 therapy and reports complete tumor eradication in 74% of MC38-bearing mice.
UID 2225GLQFJC...9jSii	Candidate B	0.700	74% in MC38 is directly stated.
UID 485Cf1sea...x44cj	Both valid	0.950	The source directly reports both the 74% complete tumor eradication in MC38-bearing mice and the T-cell-reactivation/synergistic mechanism linking local L-arginine to anti-PD-L1 therapy.
UID 545HBXE8Z...vjmAU	Candidate B	0.850	Every atom of candidate B is explicit: the combination of L-Arg bacteria with anti-PD-L1 therapy, complete tumor eradication, 74%, and MC38-bearing mice, with intratumoral delivery stated in the source. Candidate A is also supported but is a vaguer mechanistic restatement; since each added detail in B is itself supported, the more specific candidate wins.
UID 1655GP12H7...64NaS	Both valid	0.750	74% complete eradication stated; T-cell mechanism framing also supported.

Case 10openalex_w4200355303Candidate A · 15 votes · 0.667 agreement

Candidate A

Tumor-localized bacterial arginine synthesis is a strategy for sustaining a metabolically supportive tumor microenvironment rather than relying on impractical systemic arginine supplementation.

Candidate B

The therapeutic benefit of arginine depends on delivering it locally within the tumor: intratumoral L-arginine bacteria potentiate anti-PD-L1 therapy, whereas intravenous L-arginine is ineffective in part because it diffuses away from tumors.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate A	0.700	B claims intravenous arginine was ineffective, which is not stated; the text says intratumoral Arg injection was unsatisfactory and oral dosing impractical.
UID 1645CoLWok...dR8wp	Candidate A	0.900	Candidate A is directly supported by the source, which describes engineered ECN producing local L-arginine in tumors as an alternative to impractical systemic arginine supplementation; candidate B misattributes the diffusion problem to intravenous L-arginine rather than to intratumoral free-arginine injection.
UID 735HDmNaB...xCsrq	Candidate A	0.900	Candidate_a is supported because the source describes engineered ECN producing local Arg in the TME as an alternative to impractical oral Arg supplementation, while candidate_b's claim about intravenous L-arginine diffusing away is not supported.
UID 1875FFG8zd...py6Gd	Both valid	0.860	Both claims are supported in the reported mouse and engineered-bacteria context. Candidate A accurately describes local bacterial arginine synthesis as an alternative to impractical arginine supplementation. Candidate B is a compatible refinement emphasizing local delivery, intratumoral synergy with anti-PD-L1, and the weaker preliminary outcome observed with intravenous administration.
UID 1445CJFg65...QFYUV	Candidate A	0.750	B wrongly says intravenous arginine is ineffective; the text says intratumoral Arg injection diffuses away and oral Arg is impractical.
UID 1495CPkdLy...TFhGQ	Candidate A	0.800	B asserts intravenous arginine ineffective; source says oral impractical and intratumoral arginine unsatisfactory, not intravenous.
UID 2075H4GiuY...cr5BU	Both valid	0.900	The source explicitly supports candidate_a by describing the engineered bacteria's role in sustaining local arginine levels to modulate the TME, and candidate_b by contrasting the efficacy of intratumoral injection with the inefficacy of systemic/oral administration due to diffusion.
UID 1195E9SmUN...jSoiV	Both valid	0.900	The source explicitly supports that engineered bacteria sustain local arginine to support the tumor microenvironment and contrasts this with the inefficacy of intravenous arginine due to diffusion.
UID 1605FTVoVJ...5APoK	Both valid	0.900	The source explicitly supports candidate_a by describing the engineered bacteria's role in sustaining local arginine levels and candidate_b by contrasting the efficacy of intratumoral injection with the inefficacy of systemic (intravenous/oral) delivery due to diffusion.
UID 1845Hh3Wh2...jVwWe	Candidate A	0.750	B claims intravenous Arg is ineffective, but the paper says intratumorally injected Arg was unsatisfactory due to diffusion, not intravenous.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source explicitly supports that local bacterial arginine synthesis sustains the tumor microenvironment and that intratumoral injection is effective while oral/systemic delivery faces practical or efficacy limitations.
UID 2225GLQFJC...9jSii	Candidate A	0.700	B claims intravenous arginine ineffective, but the text says oral Arg is impractical and intratumoral Arg injection unsatisfactory due to diffusion, not intravenous.
UID 485Cf1sea...x44cj	Candidate A	0.900	Candidate_a directly reflects the source's rationale that local bacterial arginine synthesis overcomes impractical systemic supplementation.
UID 545HBXE8Z...vjmAU	Candidate A	0.800	Candidate B misattributes the diffusion finding: the source says intratumorally injected Arg gave unsatisfactory results probably because of rapid diffusion out of tumors, while the intravenous route it discusses is for L-Arg bacteria (preliminary data, weaker effect), not intravenous L-arginine. Candidate A's atoms — local bacterial Arg synthesis sustaining a supportive TME instead of impractical systemic Arg supplementation — are directly stated.
UID 1655GP12H7...64NaS	Candidate A	0.700	B says intravenous Arg is ineffective; the text says intratumoral Arg injection was unsatisfactory, and oral Arg impractical, not intravenous.

Case 11openalex_w4200355303Both valid · 15 votes · 0.933 agreement

Candidate A

Tumor-localized bacterial arginine synthesis is a strategy for sustaining a metabolically supportive tumor microenvironment rather than relying on impractical systemic arginine supplementation.

Candidate B

Bacteria-based local synthesis addresses the pharmacokinetic limitation of bolus arginine delivery by exploiting bacterial tumor tropism and continuous production from tumor metabolites, building on E. coli as a proven delivery platform.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.600	Both reflect the text's rationale for ammonia-recycling bacteria and E. coli as a delivery platform.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source's description of engineered ECN producing arginine continuously in the TME as an alternative to impractical arginine administration.
UID 735HDmNaB...xCsrq	Both valid	0.900	The source supports both claims: it describes local arginine synthesis by engineered bacteria to overcome impractical systemic supplementation and exploit bacterial tumor tropism and continuous production.
UID 1875FFG8zd...py6Gd	Both valid	0.950	Both candidates are supported and compatible: the first describes the overall tumor-localized arginine-synthesis strategy, while the second adds the related rationale involving bacterial tumor localization, continuous production, and E. coli as a delivery platform.
UID 1445CJFg65...QFYUV	Both valid	0.600	Both fit the described rationale: ECN recycles tumor ammonia into Arg, E. coli is widely used as a delivery platform, and Arg diffuses away from tumors.
UID 1495CPkdLy...TFhGQ	Both valid	0.600	Both align with the source's rationale: bacterial tumor presence, ammonia use, E. coli as delivery vehicle.
UID 2075H4GiuY...cr5BU	Both valid	0.900	The source text supports candidate_a by highlighting the impracticality of systemic arginine and the benefit of local synthesis via bacteria, and supports candidate_b by describing how engineered ECN exploits tumor ammonia for continuous production.
UID 1195E9SmUN...jSoiV	Both valid	0.900	The source text supports both the strategy of local arginine synthesis to overcome systemic limitations and the use of engineered E. coli for continuous production via tumor tropism.
UID 1605FTVoVJ...5APoK	Both valid	0.900	The source explicitly contrasts the impracticality of systemic arginine with the engineered bacteria's ability to synthesize local arginine from tumor metabolites, supporting both claims.
UID 1845Hh3Wh2...jVwWe	Both valid	0.700	Both describe ammonia-to-Arg bacteria sustaining local Arg in TME instead of impractical oral Arg.
UID 2215FsjxHC...ANZD6	Both valid	0.950	The source text explicitly contrasts the impracticality of systemic arginine supplementation with the engineered bacteria's ability to synthesize arginine locally from tumor ammonia, supporting both candidates' core claims.
UID 2225GLQFJC...9jSii	Both valid	0.650	Both reflect the rationale of bacterial ammonia-to-Arg local synthesis and E. coli as delivery platform.
UID 485Cf1sea...x44cj	Both valid	0.950	Both claims accurately reflect the highlighted study's shift to localized bacterial arginine production, overcoming impractical systemic or bolus delivery while using tumor ammonia and E. coli-based delivery.
UID 545HBXE8Z...vjmAU	Candidate A	0.680	Candidate A's atoms are explicit: oral Arg supplementation is impractical and the engineered ECN was built to use tumor-produced ammonia for continuous Arg synthesis sustaining a high local Arg concentration. Candidate B adds 'exploiting bacterial tumor tropism', which the source never establishes as the mechanism — it only notes bacteria can be found in tumors and later lists tumor tropism as an open question — so that atom fails.
UID 1655GP12H7...64NaS	Both valid	0.700	Both describe local bacterial Arg synthesis from ammonia replacing impractical oral/systemic Arg, with E. coli as delivery platform.

Case 12openalex_w4214873639Both valid · 15 votes · 0.933 agreement

Candidate A

Malignant epithelial subpopulations exhibit distinct lineage-associated transcriptional programs and developmental relationships rather than a single uniform tumor state.

Candidate B

The six major cell clusters are corroborated by mammary lineage marker genes including MYLK and ACTA2 for basal/myoepithelium, ESR1, FOXA1, PGR, AFF3 for mature luminal, and EZH2 for luminal progenitors.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.750	B restates the marker genes given in the paper.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source: candidate_a by the identification of distinct epithelial subpopulations with diverse features and pseudotime trajectories, and candidate_b by the explicit listing of marker genes for the six clusters.
UID 735HDmNaB...xCsrq	Both valid	0.900	The source directly supports distinct malignant epithelial subpopulations with lineage-associated trajectories and also directly lists the mammary lineage marker genes validating the six major clusters.
UID 1875FFG8zd...py6Gd	Both valid	0.980	Both candidate claims are supported by the supplied paper. The study identifies six epithelial subclusters and describes lineage-associated developmental relationships, while also explicitly linking major cell clusters to canonical mammary lineage markers.
UID 1445CJFg65...QFYUV	Both valid	0.750	B paraphrases the marker corroboration; A is supported.
UID 1495CPkdLy...TFhGQ	Both valid	0.600	Both are supported by the marker description.
UID 2075H4GiuY...cr5BU	Both valid	0.950	The source text explicitly supports both the existence of distinct lineage-associated transcriptional programs and developmental trajectories (candidate_a) and the specific marker gene assignments for the six major cell clusters (candidate_b).
UID 1195E9SmUN...jSoiV	Both valid	0.950	Candidate A is supported by the identification of distinct epithelial subpopulations with specific lineage markers and pseudotime trajectories, while Candidate B is directly confirmed by the text listing the specific marker genes for each cluster.
UID 1605FTVoVJ...5APoK	Both valid	0.950	The source text explicitly supports both the existence of distinct lineage-associated transcriptional programs and developmental trajectories (candidate_a) and the specific marker gene assignments for the six major cell clusters (candidate_b).
UID 1845Hh3Wh2...jVwWe	Both valid	0.800	Marker gene lists match the text.
UID 2215FsjxHC...ANZD6	Both valid	0.950	Both candidates are directly supported by the text: candidate_a reflects the finding of distinct subpopulations with specific lineage programs, and candidate_b lists the exact marker genes cited in the source for those clusters.
UID 2225GLQFJC...9jSii	Both valid	0.700	Both supported.
UID 485Cf1sea...x44cj	Both valid	0.900	Both claims are directly supported by the source: distinct epithelial subpopulations with lineage-associated programs and trajectories are described, and the six clusters are corroborated by the listed marker genes.
UID 545HBXE8Z...vjmAU	Candidate B	0.700	Every gene-to-lineage assignment in B matches the source sentence (MYLK/ACTA2 for basal progenitor/myoepithelium, ESR1/FOXA1/PGR/AFF3 for mature luminal, EZH2 for luminal progenitor) and its qualifier correctly scopes it to BC-A epithelial clusters by snRNA-seq marker expression. Both pass, so the more specific and fully supported B is preferred.
UID 1655GP12H7...64NaS	Both valid	0.600	Both are supported by the marker gene corroboration.

Case 13openalex_w4214873639Both valid · 15 votes · 0.933 agreement

Candidate A

Distinct malignant subpopulations occupy different spatial contexts and coincide with differing enrichment of non-malignant cell types.

Candidate B

Neutrophils were enriched in the luminal region, whereas B cells principally infiltrated the basal region.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.800	Both match the ST findings.
UID 1645CoLWok...dR8wp	Both valid	0.950	The paper directly reports malignant subclusters mapped to distinct tissue regions with discrepant stromal enrichment, and also explicitly states neutrophil enrichment in the luminal region versus B-cell infiltration in the basal region.
UID 735HDmNaB...xCsrq	Both valid	0.980	Both claims are directly supported by the source: malignant subclusters mapped to distinct tissue regions with discrepant stromal cell enrichment, and neutrophils were enriched in the luminal region while B cells principally infiltrated the basal region.
UID 1875FFG8zd...py6Gd	Both valid	0.990	Both claims are supported by the source and are compatible: the study reports distinct spatial regions and subtype distributions, along with region-specific enrichment of neutrophils and B cells.
UID 1445CJFg65...QFYUV	Both valid	0.800	Both consistent with the reported spatial pattern.
UID 1495CPkdLy...TFhGQ	Both valid	0.700	Both are supported by the spatial findings.
UID 2075H4GiuY...cr5BU	Both valid	0.950	The source text explicitly states that malignant subclusters are mapped in distinct tissue regions with discrepant stromal enrichment and confirms that neutrophils were enriched in the luminal region while B cells infiltrated the basal region.
UID 1195E9SmUN...jSoiV	Both valid	0.950	The source text explicitly states that malignant subclusters are mapped in distinct tissue regions with discrepant stromal enrichment and confirms that neutrophils were enriched in the luminal region while B cells infiltrated the basal region.
UID 1605FTVoVJ...5APoK	Both valid	0.950	The source text explicitly states that malignant subclusters map to distinct tissue regions with discrepant stromal enrichment and confirms that neutrophils were enriched in the luminal region while B cells infiltrated the basal region.
UID 1845Hh3Wh2...jVwWe	Both valid	0.850	Neutrophil/B cell regions match.
UID 2215FsjxHC...ANZD6	Both valid	0.950	The source text explicitly states that malignant subclusters map to distinct tissue regions with discrepant stromal enrichment and confirms neutrophils are enriched in the luminal region while B cells infiltrate the basal region.
UID 2225GLQFJC...9jSii	Both valid	0.700	Both supported.
UID 485Cf1sea...x44cj	Both valid	0.900	The paper reports malignant subclusters mapped to distinct tissue regions with discrepant stromal enrichment and separately states neutrophils were enriched in the luminal region while B cells mainly infiltrated the basal region.
UID 545HBXE8Z...vjmAU	Candidate B	0.750	Candidate B restates the source exactly (neutrophils enriched in the luminal region, B cells infiltrating the basal region) and its qualifier matches the paper's own framing of the spatial division of primary nontumor cells in the ST dataset. It is the more specific candidate with every added detail supported.
UID 1655GP12H7...64NaS	Both valid	0.600	Both supported by spatial results including neutrophil and B cell region enrichment.

Case 14openalex_w4214873639Both valid · 15 votes · 0.867 agreement

Candidate A

Malignant epithelial subpopulations exhibit distinct lineage-associated transcriptional programs and developmental relationships rather than a single uniform tumor state.

Candidate B

Tumor epithelial subclusters organize along differentiation trajectories in which myoepithelial cells derive from basal progenitor cells and mature luminal cells arise from luminal progenitor cells.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.700	Both are supported by the pseudotime and cluster analyses.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source: distinct epithelial subpopulations with lineage-associated programs are described, and pseudotime analysis shows myoepithelial cells from basal progenitors and mature luminal from luminal progenitors.
UID 735HDmNaB...xCsrq	Both valid	0.900	Source confirms distinct epithelial subpopulations with lineage-associated programs and the myoepithelial and luminal differentiation trajectories.
UID 1875FFG8zd...py6Gd	Both valid	0.990	Both claims are supported by the source and are compatible. Candidate_a gives the broader interpretation of distinct lineage-associated epithelial states, while candidate_b provides the specific computationally inferred differentiation trajectories.
UID 1445CJFg65...QFYUV	Both valid	0.750	Pseudotime relationships are reported and support A.
UID 1495CPkdLy...TFhGQ	Both valid	0.600	Both are supported by the pseudotime and lineage findings.
UID 2075H4GiuY...cr5BU	Both valid	0.900	The source explicitly states that malignant subpopulations exhibit distinct programs and that pseudotime analysis shows myoepithelial cells stem from basal progenitors while luminal progenitors differentiate into mature luminal cells.
UID 1195E9SmUN...jSoiV	Candidate A	0.900	The source explicitly states that malignant subclusters exhibit distinct features and lineage-associated structures (basal vs luminal), supporting candidate_a, while candidate_b's specific trajectory claims are computational inferences rather than proven lineage tracing.
UID 1605FTVoVJ...5APoK	Both valid	0.900	The source text explicitly supports both the existence of distinct epithelial subpopulations with specific markers and the differentiation trajectories linking basal progenitors to myoepithelial cells and luminal progenitors to mature luminal cells.
UID 1845Hh3Wh2...jVwWe	Both valid	0.800	Pseudotime shows myoepithelial from basal progenitors and luminal progenitors to mature luminal.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source explicitly states that malignant cells cluster into distinct subpopulations with diverse features and identifies specific differentiation trajectories where myoepithelial cells stem from basal progenitors and luminal progenitors differentiate into mature luminal cells.
UID 2225GLQFJC...9jSii	Both valid	0.700	Both supported.
UID 485Cf1sea...x44cj	Both valid	0.900	Both claims are directly supported by the source: distinct subpopulations with lineage programs (span-0001) and specific differentiation trajectories (span-0002).
UID 545HBXE8Z...vjmAU	Candidate B	0.700	Every atom of candidate B is explicit: myoepithelial cells stemmed from basal progenitor cells and luminal progenitor cells differentiated into mature luminal cells, from Monocle 2 differentiation trajectories, and the qualifier correctly flags these as computational reconstructions. It is the more specific candidate with all added details supported.
UID 1655GP12H7...64NaS	Both valid	0.600	Both are supported by the Monocle 2 trajectory results.

Case 15openalex_w4214873639Both valid · 14 votes · 0.929 agreement · 1 failed review

Candidate A

Malignant epithelial subpopulations exhibit distinct lineage-associated transcriptional programs and developmental relationships rather than a single uniform tumor state.

Candidate B

The epithelial subpopulations are organized along distinguishable luminal and basal/myoepithelial differentiation trajectories.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.750	Both are supported by the pseudotime and marker analyses.
UID 1645CoLWok...dR8wp	Both valid	0.900	The source describes distinct epithelial subpopulations with lineage-specific programs and pseudotime trajectories along luminal and basal/myoepithelial lineages, supporting both claims.
UID 735HDmNaB...xCsrq	Review failed	-	Review failed after retries: responses_json must be a JSON array
UID 1875FFG8zd...py6Gd	Both valid	0.970	Both candidates are supported as compatible descriptions. The source reports distinct epithelial subclusters and explicitly identifies luminal and basal/myoepithelial pseudotime trajectories, while appropriately not establishing in vivo temporal lineage.
UID 1445CJFg65...QFYUV	Both valid	0.750	Pseudotime revealed luminal and basal/myoepithelial lineages.
UID 1495CPkdLy...TFhGQ	Both valid	0.600	Both are supported by the trajectories.
UID 2075H4GiuY...cr5BU	Both valid	0.900	The source explicitly identifies distinct malignant epithelial subpopulations with specific markers and pathways, and uses Monocle 2 to infer luminal and basal/myoepithelial differentiation trajectories.
UID 1195E9SmUN...jSoiV	Both valid	0.950	The source explicitly identifies distinct malignant epithelial subpopulations with specific markers and pathways, and uses Monocle 2 to infer luminal and basal/myoepithelial differentiation trajectories.
UID 1605FTVoVJ...5APoK	Both valid	0.900	The source explicitly identifies distinct epithelial subpopulations with specific markers and pathways (supporting candidate_a) and uses Monocle 2 to infer luminal and basal/myoepithelial differentiation trajectories (supporting candidate_b).
UID 1845Hh3Wh2...jVwWe	Both valid	0.800	Pseudotime trajectories of luminal and basal/myoepithelial lineages.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source explicitly identifies distinct malignant epithelial subpopulations with specific marker genes and pathways, and uses Monocle 2 to infer luminal and basal/myoepithelial differentiation trajectories.
UID 2225GLQFJC...9jSii	Both valid	0.700	Both supported.
UID 485Cf1sea...x44cj	Both valid	0.900	The source reports distinct epithelial subclusters with lineage-specific markers/pathways and Monocle trajectories for luminal and basal/myoepithelial lineages, supporting both claims.
UID 545HBXE8Z...vjmAU	Candidate B	0.700	B's atoms are directly established: Monocle 2 pseudotime revealed luminal and basal/myoepithelial lineage trajectories, with myoepithelial cells stemming from basal progenitors and luminal progenitors differentiating into mature luminal cells, and its qualifier correctly limits pseudotime to ordering rather than in vivo lineage. Both pass, so the more specific and fully supported B is preferred.
UID 1655GP12H7...64NaS	Both valid	0.600	Both are supported by the trajectory analysis.

Case 16openalex_w4214873639Candidate A · 15 votes · 0.867 agreement

Candidate A

UMAP visualization of 4,093 nuclei from BC-A tumor analyzed by snRNA-seq shows nine major cell types

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate A	0.900	The Fig. 1 legend gives 4,093 nuclei and nine major cell types.
UID 1645CoLWok...dR8wp	Candidate A	0.980	The figure caption directly states UMAP visualization of 4,093 nuclei from BC-A tumor analyzed by snRNA-seq showing nine major cell types.
UID 735HDmNaB...xCsrq	Candidate A	0.970	The figure legend explicitly states UMAP visualization of 4,093 nuclei from the BC-A tumor analyzed by snRNA-seq showing nine major cell types.
UID 1875FFG8zd...py6Gd	Insufficient information	0.960	The supplied evidence supports one specific claim about BC-A, but the case does not provide the underlying statements corresponding to candidate_a and candidate_b. Therefore, it is not possible to determine which candidate is supported or whether both are valid or invalid.
UID 1445CJFg65...QFYUV	Candidate A	0.900	Fig. 1 legend states 4,093 nuclei and nine major cell types.
UID 1495CPkdLy...TFhGQ	Candidate A	0.950	Fig. 1 legend states 4,093 nuclei and nine major cell types.
UID 2075H4GiuY...cr5BU	Candidate A	1.000	The figure legend explicitly states that the UMAP visualization shows nine major cell types from 4,093 nuclei of the BC-A tumor analyzed by snRNA-seq.
UID 1195E9SmUN...jSoiV	Candidate A	1.000	The figure legend explicitly states that the UMAP visualization shows nine major cell types from 4,093 nuclei of the BC-A tumor analyzed by snRNA-seq.
UID 1605FTVoVJ...5APoK	Candidate A	0.950	The figure legend explicitly states that the UMAP visualization shows nine major cell types from 4,093 nuclei of the BC-A tumor analyzed by snRNA-seq.
UID 1845Hh3Wh2...jVwWe	Candidate A	0.950	Fig. 1 legend states 4,093 nuclei and nine major cell types.
UID 2215FsjxHC...ANZD6	Candidate A	1.000	The figure legend explicitly states that the UMAP visualization shows nine major cell types from 4,093 nuclei of the BC-A tumor analyzed by snRNA-seq.
UID 2225GLQFJC...9jSii	Candidate A	0.850	Matches Fig. 1 legend.
UID 485Cf1sea...x44cj	Candidate A	0.900	The source directly states that UMAP visualization of 4,093 nuclei shows nine major cell types.
UID 545HBXE8Z...vjmAU	Both invalid	0.550	The numbers are accurate, but the candidate is lifted from the Fig. 1b legend and asserts what a UMAP visualization displays rather than a finding the authors present as a result or conclusion, so it fails author_marked_salience and propositional_completeness as a scientific claim.
UID 1655GP12H7...64NaS	Candidate A	0.900	The Fig. 1 legend states 4,093 nuclei and nine major cell types.

Case 17openalex_w4214873639Both valid · 15 votes · 0.933 agreement

Candidate A

Cohort-level abundance patterns of defined tumor subpopulations are associated with clinically different survival and chemotherapy-response profiles.

Candidate B

Based on the defined gene signature, all of cases were divided into three discriminated subgroups (DSGs).

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.700	Three DSGs were defined, and A is a supported summary.
UID 1645CoLWok...dR8wp	Both valid	0.900	Both claims are directly supported by the source text: candidate_a's association with survival and chemotherapy response is stated, and candidate_b's division into three DSGs is explicitly quoted.
UID 735HDmNaB...xCsrq	Both valid	0.900	The source directly supports both claims: it reports associations between inferred tumor-subpopulation abundances, survival, and neoadjuvant chemotherapy response, and it states that the defined gene signature divided all cases into three DSGs.
UID 1875FFG8zd...py6Gd	Both valid	0.980	Both claims are supported and compatible: the study reports that defined gene signatures divided cases into three discriminated subgroups, and it reports associations between tumor-subpopulation abundance and survival or chemotherapy response. The broader cohort-level association claim appropriately does not imply causation, while the subgroup-division claim is a compatible refinement.
UID 1445CJFg65...QFYUV	Both valid	0.750	B is a direct quote; A is supported.
UID 1495CPkdLy...TFhGQ	Both valid	0.500	Three DSGs are stated, and the association claim holds.
UID 2075H4GiuY...cr5BU	Both valid	0.950	The source explicitly states that cases were divided into three DSGs based on a gene signature and that subpopulation abundance was associated with survival and chemotherapy response.
UID 1195E9SmUN...jSoiV	Both valid	0.900	Candidate A is supported by the abstract and results showing differential association with survival and therapeutic response; Candidate B is directly stated in the text regarding the division of cases into DSGs based on the gene signature.
UID 1605FTVoVJ...5APoK	Both valid	0.900	Candidate A is supported by the abstract and results showing differential association with survival and response; Candidate B is directly quoted from the text describing the division of cases into three DSGs.
UID 1845Hh3Wh2...jVwWe	Both valid	0.800	Three DSGs stated.
UID 2215FsjxHC...ANZD6	Both valid	0.900	Candidate A is supported by the abstract and results showing differential association with survival and therapeutic response; Candidate B is directly stated in the text regarding division into three DSGs.
UID 2225GLQFJC...9jSii	Both valid	0.700	Both supported.
UID 485Cf1sea...x44cj	Both valid	0.900	The source directly reports dividing all cases into three DSGs and associates tumor subpopulation abundances with survival and chemotherapy response, so both candidate claims are supported.
UID 545HBXE8Z...vjmAU	Candidate A	0.850	Candidate A states the paper's own reported association between deconvolution-inferred subpopulation abundance and survival/chemotherapy response. Candidate B quotes only the step of dividing cases into three discriminated subgroups, an analytic setup detail with no outcome, so it fails propositional_completeness and author_marked_salience.
UID 1655GP12H7...64NaS	Both valid	0.550	Both are supported by the METABRIC subgroup and outcome results.

Case 18openalex_w4214873639Both valid · 15 votes · 0.733 agreement

Candidate A

Cohort-level abundance patterns of defined tumor subpopulations are associated with clinically different survival and chemotherapy-response profiles.

Candidate B

The proportion of cycling luminal-B cells is increased in patients who respond to neoadjuvant chemotherapy.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.750	The cycling LumB ratio increased in NAC responders, and A is the general summary.
UID 1645CoLWok...dR8wp	Both valid	0.950	Both claims are directly supported by the source: the abstract and results describe associations between subpopulation abundances and survival/therapy response, and specifically the cycling LumB proportion is increased in NAC responders.
UID 735HDmNaB...xCsrq	Both valid	0.900	Both claims are explicitly supported by the paper: the deconvolution analyses show associations with survival and chemotherapy response, and the cycling LumB proportion is increased in responders to NAC.
UID 1875FFG8zd...py6Gd	Both valid	0.990	Both candidates are supported by the supplied source. The paper reports that DSG2 patients had the worst survival and that cycling LumB abundance increased among patients responding to neoadjuvant chemotherapy. These are reported cohort-level associations, not causal claims.
UID 1445CJFg65...QFYUV	Both valid	0.800	Cycling LumB is increased in responders.
UID 1495CPkdLy...TFhGQ	Both valid	0.550	The cycling LumB increase in responders is stated.
UID 2075H4GiuY...cr5BU	Candidate B	0.950	The source explicitly states that the ratio of cycling LumB cells significantly increased in patients who responded to neoadjuvant chemotherapy, directly supporting candidate_b.
UID 1195E9SmUN...jSoiV	Candidate B	0.950	The source explicitly states that the ratio of cycling LumB cells significantly increased in patients who responded to neoadjuvant chemotherapy.
UID 1605FTVoVJ...5APoK	Candidate B	0.900	The source explicitly states that the ratio of cycling LumB cells significantly increased in patients who responded to neoadjuvant chemotherapy.
UID 1845Hh3Wh2...jVwWe	Both valid	0.800	Cycling LumB increased in NAC responders.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source explicitly states that deconvolution revealed differential associations with survival and therapeutic response, and specifically notes that the cycling LumB cluster proportion increased in patients responding to neoadjuvant chemotherapy.
UID 2225GLQFJC...9jSii	Both valid	0.700	Both supported.
UID 485Cf1sea...x44cj	Both valid	0.900	The paper directly reports deconvolution-based associations with survival and chemotherapy response, and specifically states that the cycling LumB ratio is significantly increased in NAC responders.
UID 545HBXE8Z...vjmAU	Candidate B	0.700	The source states directly that the ratio of the cycling LumB cluster significantly increased in patients who responded to NAC, so every atom of candidate_b (population, direction, outcome) is explicit. It is a supported, more specific refinement of candidate_a's general association statement.
UID 1655GP12H7...64NaS	Both valid	0.550	Both are supported by the NAC response result.

Case 19openalex_w4214873639Both valid · 15 votes · 0.600 agreement

Candidate A

Cohort-level abundance patterns of defined tumor subpopulations are associated with clinically different survival and chemotherapy-response profiles.

Candidate B

Gene signature scores (ssGSEA) differ across METABRIC samples for six gene signatures.

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Candidate A	0.600	B is trivially vague and not a reported finding; A matches the survival and NAC associations.
UID 1645CoLWok...dR8wp	Both valid	0.900	The source explicitly reports differential survival and chemotherapy-response associations for deconvoluted tumor subpopulations, and the figure legend documents per-sample ssGSEA scores for six gene signatures.
UID 735HDmNaB...xCsrq	Candidate A	0.900	Source spans describe deconvolution of METABRIC and NAC cohorts revealing associations between tumor subpopulation abundance and survival/chemotherapy response, matching candidate_a and its conditions.
UID 1875FFG8zd...py6Gd	Both valid	0.900	Candidate A is supported by the reported association of tumor-subpopulation patterns with survival and chemotherapy response. Candidate B is a compatible, narrower description of the METABRIC ssGSEA analysis across six gene signatures; the figure legend explicitly identifies ssGSEA scores estimated for each METABRIC sample.
UID 1445CJFg65...QFYUV	Candidate A	0.800	Candidate B is a trivial heatmap statement and not the finding; A matches survival and NAC associations.
UID 1495CPkdLy...TFhGQ	Both valid	0.400	The ssGSEA heatmap of six signatures in METABRIC exists, and the association claim holds.
UID 2075H4GiuY...cr5BU	Both valid	0.950	The paper explicitly states that deconvolution revealed differential associations with survival and therapeutic response, and Figure 2d confirms ssGSEA scores were estimated for six gene signatures in METABRIC samples.
UID 1195E9SmUN...jSoiV	Both valid	0.900	The source explicitly states that deconvolution revealed differential association with survival and therapeutic response, and Figure 2d shows ssGSEA scores for six signatures across METABRIC samples.
UID 1605FTVoVJ...5APoK	Both valid	0.950	The source explicitly states that ssGSEA scores were estimated for six gene signatures in METABRIC samples and reports differential associations with survival and chemotherapy response.
UID 1845Hh3Wh2...jVwWe	Both valid	0.600	Fig 2d shows ssGSEA scores of six signatures per METABRIC sample.
UID 2215FsjxHC...ANZD6	Both valid	0.900	The source explicitly states that ssGSEA scores were estimated for six gene signatures in METABRIC samples and reports differential associations with survival and chemotherapy response.
UID 2225GLQFJC...9jSii	Candidate A	0.550	B is only a trivial figure description; A is the paper's finding.
UID 485Cf1sea...x44cj	Both valid	0.600	Both claims are supported: candidate_a matches the deconvolution-based survival and chemotherapy-response associations, and candidate_b matches the ssGSEA heatmap of six signatures across METABRIC samples.
UID 545HBXE8Z...vjmAU	Candidate A	0.800	Candidate B rests only on a figure legend describing a heatmap of ssGSEA scores; that samples 'differ' is an incidental, merely implied detail the authors never present as a result, failing author_marked_salience and paper_original_support. Candidate A is the authors' stated conclusion from the deconvolution analyses.
UID 1655GP12H7...64NaS	Candidate A	0.500	B is merely a weak, trivial statement about ssGSEA scores, while A matches the paper's findings.

Case 20openalex_w4214873639Both valid · 14 votes · 0.929 agreement · 1 failed review

Candidate A

Malignant epithelial subpopulations exhibit distinct lineage-associated transcriptional programs and developmental relationships rather than a single uniform tumor state.

Candidate B

In contrast, genomic unstable luminal-A (LumA) cells only showed an activated KRAS-downregulated signaling (Fig. 1f ).

Reviewer	Vote	Confidence	Rationale
UID 2515HDsDwo...NZSB4	Both valid	0.700	B is a direct quote and A is a general summary.
UID 1645CoLWok...dR8wp	Both valid	0.900	Source confirms distinct epithelial subpopulations with lineage relationships (candidate_a) and the specific KRAS signaling finding (candidate_b).
UID 735HDmNaB...xCsrq	Both valid	0.950	Both statements are directly supported by the source: it identifies distinct malignant epithelial subpopulations with lineage trajectories and explicitly reports the genomic unstable LumA KRAS-downregulated signaling observation.
UID 1875FFG8zd...py6Gd	Review failed	-	Automated review abstained after invalid model output: consensus response omitted items or returned invalid items: ['item_032ef1e22313fec56bf1: evidence quote is not a verbatim substring of any source span']
UID 1445CJFg65...QFYUV	Both valid	0.700	B is a direct quote; A is a supported summary.
UID 1495CPkdLy...TFhGQ	Both valid	0.550	Both are supported by the text.
UID 2075H4GiuY...cr5BU	Both valid	0.950	Candidate A is supported by the identification of distinct epithelial subclusters with specific markers and lineage trajectories, while Candidate B is directly quoted from the text describing genomic unstable LumA cells.
UID 1195E9SmUN...jSoiV	Both valid	0.950	Candidate A is supported by the identification of distinct epithelial subclusters with specific markers and trajectories in BC-A, while Candidate B is a direct quote from the text describing genomic unstable LumA cells.
UID 1605FTVoVJ...5APoK	Both valid	0.900	Candidate A is supported by the identification of distinct epithelial subclusters with specific markers and trajectories, while Candidate B is a direct quote from the text describing genomic unstable LumA cells.
UID 1845Hh3Wh2...jVwWe	Both valid	0.800	Quote accurate.
UID 2215FsjxHC...ANZD6	Both valid	0.900	Candidate A is supported by the identification of distinct epithelial subclusters with specific markers and trajectories in BC-A, while Candidate B is directly quoted from the text describing genomic unstable LumA cells.
UID 2225GLQFJC...9jSii	Both valid	0.700	Both supported.
UID 485Cf1sea...x44cj	Both valid	0.900	Candidate A is supported by the source's description of distinct malignant subpopulations with lineage trajectories, and Candidate B is a direct quotation of the reported luminal-A finding.
UID 545HBXE8Z...vjmAU	Candidate A	0.750	Candidate_b is a dangling fragment ('In contrast, ...') whose comparator is missing, and it reports a single pathway-enrichment detail rather than a finding the authors mark as a conclusion, failing propositional completeness and salience. Candidate_a's atoms — distinct lineage programs and differentiation relationships among malignant subpopulations — are established by the marker, pathway, TF and pseudotime analyses.
UID 1655GP12H7...64NaS	Both valid	0.550	Both are supported by the paper's pathway and subpopulation analyses.

1-20 of 200 casesRows

Page 1 of 10

Recent Runs?A run is one validator scoring cycle: a batch of papers is assigned, miners submit extractions, and the validator audits and scores the results.

mcr_f59f8dd8bd102a06665a36ef

Reviewer Results

Case Votes

Recent Runs?A run is one validator scoring cycle: a batch of papers is assigned, miners submit extractions, and the validator audits and scores the results.

mcr_f59f8dd8bd102a06665a36ef

Reviewer Results

Case Votes

Recent Runs

Recent Runs